You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


NICE recommends Merck’s Tepmetko for lung cancer treatment

The National Institute for Health and Care Excellence (NICE) has recommended Tepmetko (tepotinib) for the treatment of adult patients in the UK with advanced non-small cell lung cancer (NSCLC).